Nkarta Inc (NKTX)
7.55
+0.06
(+0.80%)
USD |
NASDAQ |
May 02, 12:53
Nkarta Research and Development Expense (Annual): 96.77M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 96.77M |
| December 31, 2022 | 90.90M |
| December 31, 2021 | 63.41M |
| Date | Value |
|---|---|
| December 31, 2020 | 36.22M |
| December 31, 2019 | 17.22M |
| December 31, 2018 | 4.252M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.22M
Minimum
2019
96.77M
Maximum
2023
60.90M
Average
63.41M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Cutera Inc | 21.41M |
| GT Biopharma Inc | 6.466M |
| Outlook Therapeutics Inc | 26.45M |
| IMAC Holdings Inc | -- |
| Capricor Therapeutics Inc | 36.45M |